论文部分内容阅读
1967年,Krulich等发现,下丘脑提取物有抑制生长激素(GH)释放的作用,首先提出,下丘脑存在生长激素释放抑制因子(SRIF)。10年后,Brazeau等成功地分离、提纯、鉴定了SRIF,它为14个氨基酸组成的多肽,对GH释放抑制作用具有剂量反应关系。之后,人们又陆续发现了12肽、28肽、25肽的SRIF,它们和14肽的SRIF有相同的氨基酸顺序片段,并对GH有较强的抑制作用。随着基因工程的发展,学者们得以推断出SRIF的前体和前肽原。研究表明,各种哺乳动物具有生物活性的部分差别不大,其羧基端14个氨基酸序列为保守区。目前,将SRIF基因克隆并合成SRIF已成为现实,将SRIF广泛药用于临床已为期不远。
In 1967, Krulich et al. Found that hypothalamic extracts have the effect of inhibiting the release of growth hormone (GH). First, hypothalamus is found to have somatostatin (SRIF). Ten years later, Brazeau et al. Successfully isolated, purified and characterized SRIF, a polypeptide of 14 amino acids with a dose-response relationship to the inhibition of GH release. Afterwards, people also found SRIF of 12 peptides, 28 peptides and 25 peptides in succession, which have the same amino acid sequence fragment as SRIF of 14 peptide and strong inhibitory effect on GH. With the development of genetic engineering, scholars have been able to deduce the precursors and prepropeptides of SRIF. Studies have shown that a variety of mammals have little difference in the biological activity part, the carboxy terminal 14 amino acid sequence as a conserved region. At present, the SRIF gene cloning and synthesis of SRIF has become a reality, widely used in clinical SRIF for a long time.